Vesiculo-erosive Oral Mucosal Disease—Management with Topical Corticosteroids: (2) Protocols, Monitoring of Effects and Adverse Reactions, and the Future
M.A. González-Moles1,*, and
C. Scully2
1 Professor of Oral Medicine, Departamento de Medicina Oral, School of Dentistry, Facultad de Odontología, Universidad de Granada, Campus de Cartuja sn, 18071, Granada, Spain; and
2 Dean and Director of Studies and Research, Eastman Dental Institute for Oral Health Care Sciences, University College London, University of London, UK;
View larger version (140K):
[in a new window]
|
Figure 1. Histopathological image of a lesion in a patient with mucous membrane pemphigoid. The biopsy was taken from the border of the erosive lesion, including erosive and non-erosive areas, allowing the pattern of epithelial detachment to be studied (HE x40).
|
|
View larger version (61K):
[in a new window]
|
Figure 2. Patient with oral lichen planus treated with 0.05% clobetasol propionate. The image shows aggravation of the white striae of lichen planus: (A) before treatment, (B) at 1 month after treatment.
|
|
View larger version (114K):
[in a new window]
|
Figure 3. (A) Patient who developed moon face during treatment with 0.05% clobetasol propionate in aqueous solution. (B) Complete resolution after reduction of the mouthrinse frequency.
|
|
View larger version (66K):
[in a new window]
|
Figure 4. Patient with hirsutism secondary to the use of 0.05% clobetasol propionate in aqueous solution.
|
|
View larger version (95K):
[in a new window]
|
Figure 5. Hemorrhagic effusions in the oral mucosa (A) of a patient with oral lichen planus treated with 0.05% clobetasol propionate in aqueous solution. The same effusions can also be observed in the skin of another patient (B).
|
|
Copyright © 2005 Institutional Access Guidelines
